Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Frequently asked questions
What sector does Alpha Tau Medical Ltd (DRTS) operate in?
Alpha Tau Medical Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Alpha Tau Medical Ltd (DRTS) current stock price?
As of the latest data, Alpha Tau Medical Ltd stock price is $12.89, with a previous close of $13.16. Alpha Tau Medical Ltd lost -$0.27 in the last trading session, representing a -2.05% loss.
What is Alpha Tau Medical Ltd (DRTS) current market capitalization?
Alpha Tau Medical Ltd market cap is approximately 1.19 billion.
What is Alpha Tau Medical Ltd (DRTS) Earnings Per Share (EPS)?
The trailing EPS is -$1.04, and the forward EPS is -$0.53.
What is Alpha Tau Medical Ltd (DRTS) EBITDA?
Alpha Tau Medical Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -13.78 million.
Does Alpha Tau Medical Ltd (DRTS) pay dividends?
No. Alpha Tau Medical Ltd does not pay a dividend.
When is Alpha Tau Medical Ltd (DRTS) next earnings report?
Alpha Tau Medical Ltd is expected to release its next earnings report on September 30, 2026.
What is Alpha Tau Medical Ltd (DRTS) beta (volatility) score?
Alpha Tau Medical Ltd has a beta of 1.224, suggesting it is more volatile than the market.
